Physician profile
James B Watson
NPI 1265692784
$3,813.66
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.49 · 2020: $1,099 · 2022: $510 · 2023: $1,081 · 2024: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $61.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.55 |
| Education | $61.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.99 | 2022-2024 | Linzess, Viberzi, Skyrizi |
| Conmed Corporation | $1,091.75 | 2020-2023 | Conmed Hemostasis |
| Celgene Corporation | $238.50 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $235.35 | 2019-2024 | X-Tack Endoscopic Helix Tacking System |
| Genzyme Corporation | $204.61 | 2023-2024 | |
| Ardelyx, INC. | $158.73 | 2023-2024 | Ibsrela |
| Gilead Sciences, INC. | $139.84 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.91 | 2023-2024 | Entyvio |
| Ferring Pharmaceuticals INC. | $114.34 | 2023-2024 | Rebyota |
| Janssen Biotech, INC. | $109.94 | 2020-2024 | Stelara, Simponi, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.42 | 2023-2024 | Trulance, Xifaxan |
| Madrigal Pharmaceuticals | $39.56 | 2024 | Rezdiffra |
| Organon LLC | $36.55 | 2023-2024 | Renflexis, Hadlima |
| Regeneron Healthcare Solutions, INC. | $33.64 | 2024 | Dupixent |
| Amgen INC. | $26.28 | 2023 | Amjevita, Avsola |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $21.58 | 2024 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $20.45 | 2024 | Voquezna |
| Lilly USA, LLC | $15.22 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.